Metera Pharmaceuticals Inc.
Biotechnology company · Somerville, Massachusetts, United States
Metera Pharmaceuticals Inc. is a biotechnology company headquartered in Somerville, Massachusetts, United States. Its earliest recorded incorporation is in 2016. It has received 1 US government small-business research award (SBIR/STTR) from health agencies, $1.5 million in total, most recently in 2020. It has reported private securities offerings to the US SEC, most recently $8.6 million sold in a notice filed in 2018.
Metera Pharmaceuticals at a glance
What does Metera Pharmaceuticals do?
US government research funding
1 SBIR/STTR small-business research award from US health agencies, $1.5 million in total (2020). NIH funding came from the National Heart, Lung, and Blood Institute.
Private fundraising reported to the SEC
3 Form D notices; the most recent reported $8.6 million sold (2018).
Frequently asked questions about Metera Pharmaceuticals
Where is Metera Pharmaceuticals headquartered?
Metera Pharmaceuticals Inc. is headquartered in Somerville, Massachusetts, United States.
What does Metera Pharmaceuticals do?
Metera Pharmaceuticals Inc. is a biotechnology company.
When was Metera Pharmaceuticals founded?
The earliest incorporation on record for Metera Pharmaceuticals Inc. is in 2016, according to public company registers.
Similar companies
- Biobot Analytics, Inc.Somerville, Massachusetts, United States
- Promakhos Therapeutics Inc.Somerville, Massachusetts, United States
- bluebird bio, Inc.Somerville, Massachusetts, United States
- Recursion PharmaceuticalsSalt Lake City, Utah, United States
- Vericel CorpBurlington, Massachusetts, United States
- SAB Biotherapeutics, Inc.Miami Beach, Florida, United States
- Adaptive Biotechnologies CorpSeattle, Washington, United States
- Inhibikase Therapeutics, Inc.Wilmington, Delaware, United States
Need a CRO or CDMO for your next study?
Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.
Compare quotesLast updated 2026-09-23. Data licences